Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa press release

besponsa press release

Перейти к контенту

Главное меню:

Разное
besponsa press release
FDA approves new treatment for adults with relapsed or , BESPONSA® Approved in the EU for Adult Patients with , Pfizer Receives U.S. FDA Approval for BESPONSA , Besponsa | European Medicines Agency, Besponsa Market (2019-2025) by Growth | Pfizer - openPR, Besponsa 2017-2018 U.S. Promotional Audit Report , , , .
The safety and efficacy of Besponsa were studied in a randomized trial of 326 patients with relapsed or refractory B-cell ALL who had received one or two prior treatments. Patients were randomized to receive treatment with Besponsa or an alternative chemotherapy regimen. The trial measured the percentage of patients with no evidence of disease and full recovery of blood counts after treatment (complete remission or CR). Of the 218 evaluated patients, 35.8 percent who received Besponsa experienced CR for a median 8.0 months; of the patients who received alternative chemotherapy, 17.4 percent experienced CR for a median 4.9 months.. The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).. Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved BESPONSA® (inotuzumab ozogamicin) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL)..
BESPONSA is the first and only CD22-directed antibody-drug conjugate indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BESPONSA® (inotuzumab ozogamicin) for the treatment of adults . Besponsa is a cancer medicine used to treat a type of blood cancer which affects B cells (a type of white blood cells) called B-cell precursor acute lymphoblastic leukaemia (ALL).. Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.. The "Besponsa 2017 U.S. Promotional Audit Report" report has been added to ResearchAndMarkets.com's offering. The 5 Key Questions Addressed by this. . .
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню